Myeloproliferative Neoplasms
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
7/1/2018: 12:00 AM
Ends On:
6/30/2019: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
0.5
Description:
Stephen T. Oh, MD, PhD
Assistant Professor, Medicine - Division of Hematology
Disclosures: Dr. Oh receives research support from Gilead Sciences, Incyte Corporation, Cell Therapeutics, Inc., and Janssen. Dr. Oh does consulting for Incyte Corporation.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 8-9, 2017, which was supported in part by Celgene, Novartis Pharmaceuticals, Seattle Genetics, Takeda Oncology, and Lilly USA, LLC.
Holly S. Comer, NP, ANP-BC, Outpatient Nurse Practitioner
Disclosures: Dr. Comer is on the Speakers' Bureau for Celgene Corporation and Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair, Professor of Medicine
Disclosures: Dr. Govindan does consulting for Celgene Corporation, Bayer Corporation, Roche, Glaxo Smithkline, Clovis Oncology, Boehringer Ingelheim, Helsinn Oncology, Genentech, Pfizer, Inc., Astra Zeneca, Abbvie, Inc., Inivata, and INC Research. He is on the Speakers' Bureau for Baxalta, Roche, and Abbvie, Inc.
Krystal F. Prater, RN, BSN, Nurse Coordinator
Disclosures: No financial relationships to disclose.
Saiama N. Waqar, MBBS, MSCI, Co-Chair, Assistant Professor of Medicine
Disclosures: No financial relationships to disclose.
Peter Westervelt, MD, PhD, Co-Chair, Professor of Medicine
Disclosures: No financial relationships to disclose.
Faculty
Stephen T. Oh, MD, PhD
Assistant Professor, Medicine - Division of Hematology
Disclosures: Dr. Oh receives research support from Gilead Sciences, Incyte Corporation, Cell Therapeutics, Inc., and Janssen. Dr. Oh does consulting for Incyte Corporation.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 8-9, 2017, which was supported in part by Celgene, Novartis Pharmaceuticals, Seattle Genetics, Takeda Oncology, and Lilly USA, LLC.
Planning Committee
Holly S. Comer, NP, ANP-BC, Outpatient Nurse Practitioner
Disclosures: Dr. Comer is on the Speakers' Bureau for Celgene Corporation and Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair, Professor of Medicine
Disclosures: Dr. Govindan does consulting for Celgene Corporation, Bayer Corporation, Roche, Glaxo Smithkline, Clovis Oncology, Boehringer Ingelheim, Helsinn Oncology, Genentech, Pfizer, Inc., Astra Zeneca, Abbvie, Inc., Inivata, and INC Research. He is on the Speakers' Bureau for Baxalta, Roche, and Abbvie, Inc.
Krystal F. Prater, RN, BSN, Nurse Coordinator
Disclosures: No financial relationships to disclose.
Saiama N. Waqar, MBBS, MSCI, Co-Chair, Assistant Professor of Medicine
Disclosures: No financial relationships to disclose.
Peter Westervelt, MD, PhD, Co-Chair, Professor of Medicine
Disclosures: No financial relationships to disclose.
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe recent updates on the genetic basis of MPNs and their role in prognostication and treatment decision-making in MPNs.
- Evaluate the role of JAK inhibitors and other novel therapies for MPN patients.
Additional Information:
Target Audience: This course is designed for intended for medical oncologists, and radiation oncologists, hematologists, as well as physician assistants, nurses and nurse practitioners.
Date
Publication Date: July 1, 2018
Expiration Date: June 30, 2019
Target Audience: This course is designed for intended for medical oncologists, and radiation oncologists, hematologists, as well as physician assistants, nurses and nurse practitioners.
Date
Publication Date: July 1, 2018
Expiration Date: June 30, 2019
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
- N ENGL J MED 372;5 NEJM.ORG January 29,2015.
- Arber D et al, Blood, 2016 May 19;127(20):2391-405.
- Guglielmelli et al, Blood 129 (24), 3227-3236. 2017 Mar 28.
- Alhuraiji A, et al. J Clin Oncol. 2016;34(suppl):abstract 7068.
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
